Welcome to our newsroom, where you can find up-to-date information about our corporate and scientific developments including our ad hoc releases.
Public Relations Contact
Dr. Achim Plum
SVP Corporate Development
Tel.: +49 30 24345 368
Email: pr@epigenomics.com
Latest news
Ad hoc Announcement According to §15 WpHG (German Securities Trading Act):
Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based Cancer Diagnostics
Release, Berlin, Germany
Friday, December 19, 2008
Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today entered into a collaboration and licensing agreement focusing on novel technologies and methods targeted at the diagnosis of various cancers.
Under the agreement both parties will jointly perform feasibility studies aimed at developing an integrated and fully automated instrument platform for the diagnosis of certain cancers based on DNA methylation biomarkers. In addition, Philips obtained the option to license the required technologies and biomarkers separately or in combination for diagnostic applications. The option may be exercised upon the successful completion of the feasibility studies. Financial details are not disclosed.
End of ad hoc
Contact:
Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Kleine Praesidentenstr. 1
10178 Berlin
Germany
+49 30 24345 368 (phone)
+49 30 24345 555 (fax)
achim.plum@epigenomics.com
www.epigenomics.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
|
